27 November 2015 Last patient vaccinated in GSK study
The South African Tuberculosis Vaccine Initiative (SATVI) has announced the final vaccination of participants in the GSKM72/AS01E (GSK 692342) study.
|Dr Michele Tameris|
The aim of the study is to test the efficacy, safety and immunogenicity of GSK Biologicals candidate tuberculosis (TB) vaccine GSK 692342 in preventing TB disease, in adults aged 18-50 years, living in high TB endemic regions. The study is being conducted at 12 sites in South Africa, Kenya and Zambia, including the SATVI site at Worcester.
According to Dr Michele Tameris, all eligible study participants have now received both doses of M72/AS01E. SATVI enrolled 658 of the total 3573 participants in this study. All participants will now be followed up at regular intervals for three years looking for signs and symptoms of TB.